Advanced Filters
noise

Heart Disease Clinical Trials

A listing of Heart Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 2,809 clinical trials
D Diana Yanez, BSN, RN

Multi-center Collaborative to Enhance Quality and Outcomes in the Management of Cardiogenic Shock

This large real-world international prospective registry will provide a unique opportunity to comprehensively understand the contemporary management, clinical course and short as well as long-term outcomes of all Cardiogenic Shock (CS) patients cared for at four high volume dedicated shock care centers. As the first true North American multicenter CS …

18 - 100 years of age Both Phase N/A
F Federico Pappalardo, MD

Study on Early Intra-aortic Balloon Pump Placement in Acute Decompensated Heart Failure Complicated by Cardiogenic Shock

The aim of the study is to demonstrate the superiority of early intra-aortic balloon pump implantation at admission over local clinical practice (pharmacological only) in acute decompensated heart failure patients with cardiogenic shock, with respect to 60-day survival or successful bridge to heart replacement therapies (heart transplant or Left Ventricular …

18 - 75 years of age Both Phase 4
D Dan Jones

Genomic Determinants of Outcome in Cardiogenic Shock

The aim of this project is to understand the heterogeneity of both the immune consequences and treatment responses in CS. We will explore this heterogeneity through identification of transcriptomic sub-phenotypes and their association with outcomes, including therapeutic responses.

18 - 80 years of age Both Phase N/A
C Christian Schulze, Prof.

ECMOsorb Trial - Impact of a VA-ECMO in Combination With CytoSorb in Critically Ill Patients With Cardiogenic Shock

In the ECMOsorb study the impact of a veno-arterial -ECMO in combination with an extracorporeal cytokine hemadsorption system in critically ill patients with cardiogenic shock is to be examined

18 - 80 years of age Both Phase N/A

Williams Syndrome (WS) and Supravalvar Aortic Stenosis (SVAS) DNA and Tissue Bank

Williams syndrome is a rare genetic disorder occurring in 1:8000-12,000 individuals. It is caused by the deletion of 25-27 coding genes, including elastin (ELN) on the 7th human chromosome. Haploinsufficiency for these genes leads to the features of the condition, including Distinctive facial features; Characteristic vascular problems including hypertension, focal …

1 - 85 years of age Both Phase N/A
X Xiangbin Pan, Dr

COMParison of the EffecT of dEvice Closure in Alleviating Migraine With PFO (COMPETE-2)

Migraine attacks are episodic disorder that affects approximately 12% of the population, and studies have shown that 41-48% of migraineurs have a combination of patent foramen ovale (PFO). Clinical Observational studies have been linking PFO occlusion with the effectiveness in improving migraine symptoms and reducing the frequency of attacks. However, …

18 - 65 years of age Both Phase 4
M Maja Maraldo

Imaging Versus Cardiac Biomarker Monitored HER2 Directed Therapy in Patients With Breast Cancer

Due to a risk of heart failure during HER2 directed therapy in breast cancer, treatment is monitored with imaging of myocardial function, which is resource demanding for both patients and the health care system. The purpose of this study is to evaluate, if biomarkers can replace imaging based examinations of …

18 - 90 years of age Female Phase N/A

Ivabradine in Cirrhotic Cardiomyopathy

A total of 130 patients with liver cirrhosis who fulfill the criteria of the study, and who have been found to have left ventricular diastolic dysfunction on a screening 2D echocardiography, will then be randomized by Block randomization technique, to two arms in a ratio 1:1(Group A) will receive carvedilol+ …

18 - 65 years of age Both Phase N/A

Left Ventricular Unloading to Improve Outcome in Cardiogenic Shock Patients on VA-ECMO

Prospective, multi-center, randomized (1:1), controlled trial of Impella for active left ventricular unloading on top of veno-arterial extracorporeal membrane oxygenation vs. veno-arterial extracorporeal membrane oxygenation alone for the treatment of cardiogenic shock.

18 - 80 years of age Both Phase N/A
M Mridula A. George

Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted

This study proposes that the addition of statins reduces the treatment delays or early discontinuations secondary to cardiotoxicity in patients with Stage I-III HER2 positive breast being treated with anti-HER2 therapy.

18 - 100 years of age Female Phase 2

Rewrite in simple language using AI